InMed Pharmaceuticals Inc. (C:IN*CA)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEDAR
Company Contact
Address: 200 Granville St Suite 340
Tel: N/A
IR: See website
Key People
William J. Garner
Chairman of the Board
Eric A. Adams
President, Chief Executive Officer, Director
Jeffrey M. Charpentier
Chief Financial Officer, Corporate Secretary
Alexandra D.J. Mancini
Senior Vice President - Clinical and Regulatory Affairs
Josh Blacher
Chief Business Officer
Abo Mohammed
Chief Medical Officer
Business Overview
InMed Pharmaceuticals Inc. is a pre-clinical-stage biopharmaceutical company. The Company specializes in the research and development of cannabinoid-based therapies combined with drug delivery systems. The Company operates through the segment of research and development of pharmaceutical cannabis based-therapies. The Company is working on two products, which include INM-750, for the treatment of Epidermolysis Bullosa (EB), and INM-085, for the treatment of Glaucoma. The INM-750 is a therapy developed for EB designed specifically to modulate disease activity and to alleviate symptoms. The INM-085 is designed as a dual-action cannabinoid ocular therapy. INM-085 is designed as a topical formulation to be administered directly to the eye. It is working on the development of several cannabinoid-based treatments for multiple diseases, including ocular, dermatology, cancer, inflammation, pain and arthritis disease areas. Its subsidiary is Biogen Sciences Inc. (BSI).
Financial Overview
For the six months ended 31 December 2018, InMed Pharmaceuticals Inc revenues was not reported. Net loss increased 63% to C$5.5M. Higher net loss reflects Share-based payments increase from C$933K to C$2.4M (expense), Research and development increase of 98% to C$1.6M (expense). Basic Earnings per Share excluding Extraordinary Items remained flat at -C$0.03.
Employees: 14 as of Sep 30, 2006
Reporting Currency: Canadian Dollars
Enterprise value: $37.27M as of Mar 31, 2019
Annual revenue (TTM): $0.00M as of Mar 31, 2019
EBITDA (TTM): -$10.94M as of Mar 31, 2019
Net annual income (TTM): -$10.65M as of Mar 31, 2019
Free cash flow (TTM): -$5.91M as of Mar 31, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 172,283,633 as of Jun 6, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization